Market Closed -
Nasdaq
16:00:00 2024-04-30 EDT
|
5-day change
|
1st Jan Change
|
31.77
USD
|
-0.41%
|
|
-6.56%
|
-22.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,574
|
4,090
|
4,343
|
1,821
|
2,799
|
2,170
|
-
|
-
|
Enterprise Value (EV)
1 |
1,567
|
3,505
|
4,237
|
611.1
|
1,539
|
1,357
|
1,726
|
1,794
|
P/E ratio
|
-19.3
x
|
-28.1
x
|
-21.5
x
|
-6.44
x
|
-6.22
x
|
-5.91
x
|
-6
x
|
-6.92
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
36.6
x
|
188
x
|
93
x
|
13.9
x
|
35.7
x
|
14.1
x
|
9.95
x
|
7.56
x
|
EV / Revenue
|
36.5
x
|
161
x
|
90.7
x
|
4.65
x
|
19.6
x
|
8.82
x
|
7.92
x
|
6.25
x
|
EV / EBITDA
|
-31.4
x
|
-28.8
x
|
-22.2
x
|
-2.38
x
|
-3.88
x
|
-3.38
x
|
-4.59
x
|
-4.96
x
|
EV / FCF
|
-33.4
x
|
-36.4
x
|
7.64
x
|
-2.18
x
|
-4.39
x
|
-5.13
x
|
-5.22
x
|
-5.72
x
|
FCF Yield
|
-2.99%
|
-2.75%
|
13.1%
|
-45.9%
|
-22.8%
|
-19.5%
|
-19.1%
|
-17.5%
|
Price to Book
|
-
|
-
|
5.57
x
|
3.22
x
|
3.46
x
|
8.62
x
|
-30.4
x
|
112
x
|
Nbr of stocks (in thousands)
|
38,304
|
48,158
|
52,872
|
53,228
|
67,999
|
68,308
|
-
|
-
|
Reference price
2 |
41.09
|
84.93
|
82.14
|
34.21
|
41.16
|
31.77
|
31.77
|
31.77
|
Announcement Date
|
20-03-16
|
21-03-01
|
22-02-28
|
23-02-23
|
24-02-27
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
42.98
|
21.8
|
46.7
|
131.4
|
78.5
|
153.8
|
218
|
286.9
|
EBITDA
1 |
-49.96
|
-121.7
|
-190.5
|
-256.9
|
-396.7
|
-401
|
-376.3
|
-361.8
|
EBIT
1 |
-51.52
|
-124.9
|
-195.3
|
-263.2
|
-401.5
|
-385.9
|
-374.2
|
-348.2
|
Operating Margin
|
-119.89%
|
-572.69%
|
-418.2%
|
-200.3%
|
-511.46%
|
-250.89%
|
-171.65%
|
-121.36%
|
Earnings before Tax (EBT)
1 |
-70.29
|
-119.3
|
-191
|
-261.6
|
-363.9
|
-353.6
|
-360.7
|
-335.7
|
Net income
1 |
-70.29
|
-119.3
|
-191
|
-282.5
|
-367.3
|
-333.7
|
-340.8
|
-321.5
|
Net margin
|
-163.56%
|
-547.35%
|
-408.99%
|
-214.99%
|
-467.9%
|
-216.97%
|
-156.32%
|
-112.04%
|
EPS
2 |
-2.130
|
-3.020
|
-3.820
|
-5.310
|
-6.620
|
-5.372
|
-5.293
|
-4.590
|
Free Cash Flow
1 |
-46.87
|
-96.2
|
554.7
|
-280.3
|
-350.7
|
-264.2
|
-330.3
|
-313.8
|
FCF margin
|
-109.06%
|
-441.27%
|
1,187.79%
|
-213.32%
|
-446.75%
|
-171.78%
|
-151.51%
|
-109.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-16
|
21-03-01
|
22-02-28
|
23-02-23
|
24-02-27
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
9.285
|
26.3
|
24.2
|
31.3
|
30.3
|
38
|
32.5
|
54.5
|
34.6
|
-43.1
|
32.06
|
52.89
|
33.69
|
40.58
|
28.11
|
EBITDA
1 |
-46.13
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-164.1
|
-93.59
|
-91.46
|
-97.07
|
-102.9
|
-
|
EBIT
1 |
-47.33
|
-54.4
|
-60
|
-68.3
|
-67.2
|
-75.4
|
-87.7
|
-74.6
|
-73.9
|
-165.3
|
-97.66
|
-91.02
|
-104.2
|
-93.36
|
-136.3
|
Operating Margin
|
-509.77%
|
-206.84%
|
-247.93%
|
-218.21%
|
-221.78%
|
-198.42%
|
-269.85%
|
-136.88%
|
-213.58%
|
383.53%
|
-304.64%
|
-172.09%
|
-309.26%
|
-230.1%
|
-484.81%
|
Earnings before Tax (EBT)
1 |
-46.75
|
-53
|
-58.9
|
-66.6
|
-64
|
-72.1
|
-81.2
|
-65.6
|
-63.9
|
-153.2
|
-88.84
|
-77.64
|
-93.79
|
-100.2
|
-125.5
|
Net income
1 |
-46.75
|
-53
|
-63.4
|
-70
|
-66.2
|
-82.9
|
-81.9
|
-66.6
|
-64
|
-154.8
|
-90.72
|
-72.22
|
-96.53
|
-78.31
|
-125.5
|
Net margin
|
-503.53%
|
-201.52%
|
-261.98%
|
-223.64%
|
-218.48%
|
-218.16%
|
-252%
|
-122.2%
|
-184.97%
|
359.16%
|
-283.01%
|
-136.55%
|
-286.53%
|
-192.99%
|
-446.52%
|
EPS
2 |
-0.9400
|
-1.000
|
-1.200
|
-1.320
|
-1.240
|
-1.560
|
-1.540
|
-1.250
|
-1.180
|
-2.530
|
-1.345
|
-1.062
|
-1.428
|
-1.395
|
-1.593
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-03
|
22-02-28
|
22-05-05
|
22-08-04
|
22-11-08
|
23-02-23
|
23-05-05
|
23-08-08
|
23-11-07
|
24-02-27
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
7.21
|
585
|
106
|
1,210
|
1,260
|
814
|
444
|
376
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-46.9
|
-96.2
|
555
|
-280
|
-351
|
-264
|
-330
|
-314
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-26.8%
|
-42%
|
-60%
|
-78.7%
|
-126%
|
-197%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
14.70
|
10.60
|
11.90
|
3.690
|
-1.050
|
0.2800
|
Cash Flow per Share
2 |
-
|
-
|
11.20
|
-5.140
|
-6.270
|
0.5200
|
0.6200
|
-
|
Capex
1 |
6.24
|
6.45
|
4.7
|
6.8
|
2.9
|
8.62
|
12.9
|
18.2
|
Capex / Sales
|
14.53%
|
29.57%
|
10.06%
|
5.18%
|
3.69%
|
5.6%
|
5.9%
|
6.34%
|
Announcement Date
|
20-03-16
|
21-03-01
|
22-02-28
|
23-02-23
|
24-02-27
|
-
|
-
|
-
|
Last Close Price
31.77
USD Average target price
69.89
USD Spread / Average Target +119.98% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.81% | 2.17B | | -3.46% | 102B | | +1.41% | 96.09B | | +2.13% | 22.28B | | -15.84% | 21.4B | | -9.35% | 18.14B | | -39.98% | 17.02B | | -14.65% | 16.09B | | +4.39% | 13.83B | | +31.35% | 11.97B |
Bio Therapeutic Drugs
|